The management of diabetic macular oedema

被引：0
作者：
Ross, Adam H. [1 ]
Bailey, C. Clare [1 ]
机构：
[1] Bristol Eye Hosp, Dept Ophthalmol, Lower Maudlin St, Bristol BS1 2LX, Avon, England
来源：
SAUDI JOURNAL OF OPHTHALMOLOGY | 2011年 / 25卷 / 02期
关键词：
Diabetic macular oedema; Laser photocoagulation; Intravitreal steroids; VEGF inhibitors;
D O I：
10.1016/j.sjopt.2011.01.011
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Diabetic macular oedema (DMO) is a significant cause of visual loss in the working population. Focal/grid photocoagulation remains an effective treatment for DMO and the benchmark to which clinicians compare other newer treatment modalities. There are, however, patients who do not respond adequately or who are refractory to laser photocoagulation. This has led to the development of newer treatments such as the intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors as well as intravitreal corticosteroid releasing delivery systems. Cataract formation and raised intraocular pressure remain the major disadvantages of corticosteroid use. There is mounting evidence that intravitreal VEGF inhibitors with or without combined laser photocoagulation will become the gold standard treatment for DMO. (C) 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.
引用
收藏
页码：123 / 129
页数：7
相关论文
共 45 条
  • [1] Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy
    Abraham, Prema
    Adelman, Ron A.
    Alfaro, Daniel Virgil, III
    Anand, Rajiv
    Antoszyk, Andrew
    Bergsma, Donald
    Hartnett, Mary Elizabeth
    Brucker, Alexander J.
    Carr, Tyree
    Casey, Raynor C.
    Rubino, John
    Chandler, Thomas W.
    Charles, Steven
    Chaudhry, Nauman
    Combs, James
    Doft, Bernard
    Young, Lucy H. Y.
    Drouilhet, John H.
    Dugel, Pravin U.
    Feman, Stephen S.
    Finkelstein, Daniel
    Foster, Robert E.
    Petersen, Michael R.
    Fox, Gregory
    Garretson, Bruce
    Gieser, Jon P.
    Gentile, Ronald C.
    Giovinazzo, Vincent
    Glazer, Louis
    Goodart, Roy A.
    Gottlieb, Justin
    Greven, Craig
    Grizzard, William S.
    Hainsworth, Dean P.
    Halperin, Lawrence
    Heier, Jeffrey S.
    Jackson, William
    Kubacki, Joseph J.
    Kanter, Eric D.
    Keyser, Bruce
    Kingsley, Ronald
    Ko, Paula
    Kokame, Gregg T.
    Kuppermann, Baruch
    Lambert, H. Michael
    Lewis, Hilel
    Lewis, Richard Alan
    Marcus, Dennis
    Nussbaum, Julian
    Maturi, Raj K.
    [J]. OPHTHALMOLOGY, 2006, 113 (12) : 2221 - 2230
  • [2] INCREASED VASCULAR ENDOTHELIAL GROWTH-FACTOR LEVELS IN THE VITREOUS OF EYES WITH PROLIFERATIVE DIABETIC-RETINOPATHY
    ADAMIS, AP
    MILLER, JW
    BERNAL, MT
    DAMICO, DJ
    FOLKMAN, J
    YEO, TK
    YEO, KT
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (04) : 445 - 450
  • [3] Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial
    Ahmadieh, Hamid
    Ramezani, Alireza
    Shoeibi, Nasser
    Bijanzadeh, Bijan
    Tabatabaei, Ali
    Azarmina, Mohsen
    Soheilian, Masoud
    Keshavarzi, Gholamreza
    Mohebbi, Mohammad-Reza
    [J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 246 (04) : 483 - 489
  • [4] Inhibition of PKC β by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients
    Aiello, LP
    Clermont, A
    Arora, V
    Davis, MD
    Sheetz, MJ
    Bursell, SE
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2006, 47 (01) : 86 - 92
  • [5] Akduman L, 1999, OPHTHALMIC SURG LAS, V30, P706
  • [6] Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
  • [7] Bunce C., 2008, CAUSES BLIND PARTIAL
  • [8] Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema - A pilot study
    Chew, E.
    Strauber, S.
    Beck, R.
    Aiello, L. P.
    Antoszyk, A.
    Bressler, N.
    Browning, D.
    Danis, R.
    Fan, J.
    Flaxel, C.
    Friedman, S.
    Glassman, A.
    Kollman, C.
    Lazarus, H.
    Patel, S.
    Callanan, D.
    Elman, M.
    Raden, R.
    Sharuk, G.
    Arrigg, P.
    Schlossman, D.
    Davidorf, F.
    Chambers, R.
    Li, H.
    Drouilhet, J.
    DiLoreto, D., Jr.
    Benner, J.
    Butler, J.
    Chan, C.
    Lin, S.
    Lyon, A.
    Mathura, J.
    Ie, D.
    Lipkowitz, J.
    Shami, M.
    Gonzalez, V.
    Vann, V.
    Wong, K.
    Niffenegger, J.
    Singerman, L.
    Miller, D.
    Gross, J.
    Fishburne, B.
    Garcia, Charles A.
    Garcia, C.
    Foster, W.
    Baker, C.
    Goodart, R.
    Faber, D.
    Mehr, D.
    [J]. OPHTHALMOLOGY, 2007, 114 (06) : 1190 - 1196
  • [9] A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema
    Cunningham, ET Jr
    Adamis, AP
    Altaweel, M
    Aiello, LP
    Bressler, NM
    D'Amico, DJ
    Goldbaum, M
    Guyer, DR
    Katz, B
    Patel, M
    Schwartz, SD
    [J]. OPHTHALMOLOGY, 2005, 112 (10) : 1747 - 1757
  • [10] Diabetic Retinopathy Clinical Research Network, 2008, OPHTHALMOLOGY, V115
12345